3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol and Pain

3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol has been researched along with Pain* in 2 studies

Reviews

1 review(s) available for 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol and Pain

ArticleYear
Progress in the development of more effective and safer analgesics for pain management.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Opioid analgesics have been used for thousands of years in the treatment of pain and related disorders, and have become among the most widely prescribed medications. Among opioid analgesics, mu opioid receptor (MOR) agonists are the most commonly used and are indicated for acute and chronic pain management. However, their use results in a plethora of well-described side-effects. From selective delta opioid receptor (DOR) and kappa opioid receptor (KOR) agonists to multitarget MOR/DOR and MOR/KOR ligands, medicinal chemistry provided different approaches aimed at the development of opioid analgesics with an improved pharmacological and tolerability fingerprint. The emergent medicinal chemistry strategy to develop ameliorated opioid analgesics is based upon the concept that functional selectivity for G-protein signalling is necessary for the therapeutic effect, whether β-arrestin recruitment is mainly responsible for the manifestation of side effects, including the development of tolerance after repeated administrations. This review summarises most relevant biased MOR, DOR, KOR and multitarget MOR/DOR ligands synthesised in the last decade and their pharmacological profile in "in vitro" and "in vivo" studies. Such biased ligands could have a significant impact on modern drug discovery and represent a new strategy for the development of better-tolerated drug candidates.

    Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pain; Pain Management; Receptors, Opioid, mu; Structure-Activity Relationship

2019

Other Studies

1 other study(ies) available for 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol and Pain

ArticleYear
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Here we report on the design, synthesis, and biological characterization of novel κ opioid (KOP) receptor ligands of diphenethylamines. In opioid receptor binding and functional assays, the N-cyclobutylmethyl substituted derivative 4 (HS665) showed the highest affinity and selectivity for the KOP receptor and KOP agonist potency. Compound 4 inhibited acetic acid induced writhing after subcutaneous administration in mice via KOP receptor-mediated mechanisms, being equipotent as an analgesic to the KOP agonist U50,488.

    Topics: Acetic Acid; Analgesics; Animals; Drug Discovery; Mice; Nociception; Pain; Phenethylamines; Receptors, Opioid, kappa

2012